{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018205","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2022-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.130435+00:00","generated_at":"2026-06-23T13:07:53.767060+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relay Therapeutics reports 88% ORR at RP2D for RLY-4008 in FGFR2 fusion CCA","bullets":["At RP2D (70 mg QD), ORR 88% (15/17), confirmed ORR 82.4% (14/17), disease control rate 100%.","All-dose ORR 63.2% (24/38), confirmed ORR 57.9% (22/38), DCR 94.7%.","68% of patients remain on treatment; median follow-up 6 months (range <0.1-18.5).","No grade 4/5 treatment-related AEs; most common low-grade stomatitis (48%) and PPE (46%).","Abstract selected for oral presentation at ESMO Congress 2022 on Sept 11."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018205","json":"https://secwatch.observer/filing/0000950170-22-018205.json","markdown":"https://secwatch.observer/filing/0000950170-22-018205.md","text":"https://secwatch.observer/filing/0000950170-22-018205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022018205/0000950170-22-018205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022018205/rlay-20220907.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T13:07:53.767060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}